{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Overall response rate was assessed according to Immune-related Response Criteria (irRC) (Wolchok, Hoos et al. 2009). ORR is the number of participants with a best overall response of irCR or irPR.\n\nirCR is defined as complete disappearance of all lesions with no new lesions; irPR as a ≥50% decrease in tumor burden from baseline; both are confirmed ≥4 weeks after initial documentation.\n\nOnly participants with adequate irRC tumor assessments (baseline and ≥1 post-baseline) and without major protocol deviations, were included in the analysis.","groups":[{"description":"Participants received a 0.8 or 1 mg of Pegilodecakin QD administered SC with Pazopanib 800 mg orally QD.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG000","title":"Part G: Pegilodecakin 0.8/1 mg + Pazopanib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received at least one dose of study intervention(s) and had an adequate irRC tumor assessment were included in the analysis.","reportingStatus":"POSTED","timeFrame":"From Date of First Dose of Study Drug until Disease Progression or Death (Up to 11 months)","title":"Part G: Number of Participants With Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}